Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.

Chk1, a serine/threonine protein kinase that participates in transducing DNA damage signals, is an attractive target due to its involvement in tumor initiation and progression. As a novel Chk1 inhibitor, the triazolone's bioactivity mechanism is not clear. In this study, we carried out an integrated computational study that combines molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations to identify the key factors necessary for the bioactivities. With the aim of discerning the structural features that affect the inhibitory activity of triazolones, MK-8776, a Chk1 inhibitor that reached the clinical stage, was also used as a reference for simulations. A comparative analysis of the triazolone inhibitors at the molecular level offers valuable insight into the structural and energetic properties. A general feature is that all the studied inhibitors bind in the pocket characterized by residues Leu14, Val22, Ala35, Glu84, Tyr85, Cys86, and Leu136 of Chk1. Moreover, introducing hydrophobic groups into triazolone inhibitors is favorable for binding to Chk1, which is corroborated by residue Leu136 with a relatively large difference in the contribution between MK-8776 and five triazolones to the total binding free energies. A hydrogen bond between the polar hydrogen atoms at R1 and Cys86 can facilitate proper placement of the inhibitor in the binding pocket of Chk1 that favors binding. However, the introduction of hydrophilic groups into the R2 position diminishes binding affinity. The information provided by this research is of benefit for further rational design of novel promising inhibitors of Chk1.

[1]  Huanxiang Liu,et al.  Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.

[2]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[3]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[4]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[5]  H. Gohlke,et al.  Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.

[6]  Gerald W. Shipps,et al.  Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[7]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[8]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[9]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[10]  Laura Sepp-Lorenzino,et al.  Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. , 2012, Bioorganic & medicinal chemistry letters.

[11]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[12]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[13]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[14]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[15]  Lawrence C Kuo,et al.  Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[16]  Laura Sepp-Lorenzino,et al.  Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[17]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[18]  David Parry,et al.  Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[19]  Philip J. Merta,et al.  Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[20]  Jin Qin,et al.  Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors , 2011, J. Chem. Inf. Model..

[21]  Wei Zhang,et al.  Characterization of Domain-Peptide Interaction Interface , 2009, Molecular & Cellular Proteomics.

[22]  J. Bartek,et al.  Mammalian G1- and S-phase checkpoints in response to DNA damage. , 2001, Current opinion in cell biology.

[23]  Xiaojie Xu,et al.  Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models , 2006 .

[24]  S. Singh,et al.  Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. , 2013, Journal of theoretical biology.

[25]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[26]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[27]  Laura Sepp-Lorenzino,et al.  Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. , 2007, Bioorganic & medicinal chemistry letters.

[28]  Huijun Sun,et al.  Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM–GBSA calculation , 2011, J. Comput. Chem..

[29]  E. Moler,et al.  CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo , 2007, Clinical Cancer Research.

[30]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[31]  P. Carrupt,et al.  Structural insights of SIR2rp3 proteins as promising biotargets to fight against Chagas disease and leishmaniasis. , 2013, Molecular bioSystems.

[32]  G. Schwartz,et al.  Targeting Checkpoint Kinase 1 in Cancer Therapeutics , 2007, Clinical Cancer Research.

[33]  B. Kuhn,et al.  Validation and use of the MM-PBSA approach for drug discovery. , 2005, Journal of medicinal chemistry.

[34]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[35]  G. McArthur,et al.  Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.

[36]  P. Kovar,et al.  Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[37]  Yan Li,et al.  Discovery of Novel Checkpoint Kinase 1 Inhibitors by Virtual Screening Based on Multiple Crystal Structures , 2011, J. Chem. Inf. Model..

[38]  Yun Dai,et al.  The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair , 2013, Molecular Cancer Therapeutics.

[39]  Tingjun Hou,et al.  Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking , 2011, J. Comput. Chem..

[40]  E. Langella,et al.  In silico investigation and targeting of amyloid β oligomers of different size. , 2013, Molecular bioSystems.

[41]  Saul H Rosenberg,et al.  Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[42]  Youyong Li,et al.  Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. , 2013, Molecular bioSystems.

[43]  J. Breed,et al.  Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration. , 2010, Bioorganic & medicinal chemistry letters.

[44]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[45]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[46]  T. Fischmann,et al.  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2. , 2011, Bioorganic & medicinal chemistry letters.

[47]  Kenji Onodera,et al.  Evaluations of Molecular Docking Programs for Virtual Screening , 2007, J. Chem. Inf. Model..

[48]  M. Bartucci,et al.  Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. , 2013, Cancer treatment reviews.

[49]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[50]  Jon Read,et al.  Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[51]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[52]  Chang Park,et al.  Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[53]  D. Clawson,et al.  Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor , 2014, Investigational New Drugs.

[54]  V. Oza,et al.  Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[55]  J. Rosen,et al.  Chk1 is haploinsufficient for multiple functions critical to tumor suppression. , 2004, Cancer cell.

[56]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[57]  Y. A. Minamishima,et al.  Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. , 2000, Genes & development.

[58]  S. Robinson,et al.  CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs , 2012, Clinical Cancer Research.

[59]  C. McGowan,et al.  Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[60]  J. Bartek,et al.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. , 2003, Cancer cell.